The Impact of Acetazolamide and Methazolamide on Exercise Performance in Normoxia and Hypoxia.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing physiological literature without systematic review methodology
PubMed 36802203 · doi:10.1089/ham.2022.0134
What was done
This narrative review synthesized published evidence regarding the effects of two carbonic anhydrase inhibitors, acetazolamide and methazolamide, on exercise performance under normoxic and hypoxic conditions. The authors evaluated mechanisms related to ventilation, arterial oxygenation, acute mountain sickness, and comparative human studies on diaphragmatic and locomotor muscle strength.
What was found
The abstract reports no numerical values, effect sizes, or confidence intervals. It qualitatively reports that acetazolamide impairs exercise performance in normoxia but may be beneficial in hypoxia, and notes that comparative studies on muscle strength suggest methazolamide may be the preferred carbonic anhydrase inhibitor when preserving physical performance at high altitude is required.
Why it matters
Carbonic anhydrase inhibitors are standard for acute mountain sickness, but understanding drug-specific trade-offs on muscle strength helps optimize pharmacological choices for physical exertion at altitude.
Limits
This is a narrative review rather than a systematic review or meta-analysis, with no study selection criteria, risk-of-bias assessment, or pooled quantitative data provided in the abstract. Specific sample sizes, dosing regimens, and performance metrics are not reported.
Cited by
- supports Diamox (acetazolamide) causes mild metabolic acidosis and increases SpO2, but reliably reduces cognitive and physical performance.